JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 19, 2004; DOI: 10.1124/jpet.104.074468


0022-3565/05/3122-733-741$20.00
JPET 312:733-741, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.074468v1
312/2/733    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ralph, R. J.
Right arrow Articles by Caine, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ralph, R. J.
Right arrow Articles by Caine, S. B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

BEHAVIORAL PHARMACOLOGY

Dopamine D1 and D2 Agonist Effects on Prepulse Inhibition and Locomotion: Comparison of Sprague-Dawley Rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J Mice

Rebecca J. Ralph, and S. Barak Caine

Alcohol and Drug Abuse Research Center, McLean Hospital—Harvard Medical School, Belmont, Massachusetts

D2 receptors have been studied in relation to therapeutic uses of dopaminergic drugs, and psychomotor stimulant effects [as manifested by decreased prepulse inhibition (PPI) of startle and increased locomotor activity] are hallmark behavioral effects of D2 agonists in rats. Genetic studies with mutant mice might be useful in this line of investigation; however, recent studies suggest that mice differ from rats with respect to D2 agonist effects. Accordingly, we studied a wide range of doses of the D2-like agonist quinelorane (0.0032–5.6 mg/kg) and the D1-like agonist R-6-Br-APB [R(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] (0.032–5.6 mg/kg) in outbred Sprague-Dawley rats, outbred Swiss-Webster mice, and inbred 129X1/SvJ, C57BL/6J, and DBA/2J mice. Whereas the D2 agonist dose-dependently decreased PPI and increased locomotion in rats, neither of these effects was observed in outbred or inbred mice. In contrast, the D1 agonist reduced PPI and increased locomotion in Sprague-Dawley rats and in Swiss-Webster, 129X1/SvJ, and C57BL/6J mice. Neither agonist decreased PPI in DBA/2J mice, although PPI was increased in this strain by a D2 antagonist. Pretreatment with either the D2 antagonist eticlopride (1 mg/kg) or the D1 antagonist SCH39166[(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naptho-(2,1-b)azepine] (1 mg/kg) prevented the PPI-disruptive effects of quinelorane in rats and R-6-Br-APB in mice, suggesting receptor interactions in both species. In summary, psychomotor stimulant effects of a D2 agonist that were robustly observed in outbred rats were absent in several outbred and inbred strains of mice. These results may have implications for the study of mutant mice to investigate genes involved in psychomotor function in humans.


Received July 19, 2004; accepted October 14, 2004.

Address correspondence to: Rebecca J. Ralph, Alcohol and Drug Abuse Research Center, McLean Hospital—Harvard Medical School, 115 Mill Street, Belmont, MA 02478. E-mail: rralph{at}mclean.harvard.edu




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. B. Caine, M. Thomsen, K. I. Gabriel, J. S. Berkowitz, L. H. Gold, G. F. Koob, S. Tonegawa, J. Zhang, and M. Xu
Lack of Self-Administration of Cocaine in Dopamine D1 Receptor Knock-Out Mice
J. Neurosci., November 28, 2007; 27(48): 13140 - 13150.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Johnson, R. T. Fremeau Jr, J. L. Duncan, R. C. Renteria, H. Yang, Z. Hua, X. Liu, M. M. LaVail, R. H. Edwards, and D. R. Copenhagen
Vesicular Glutamate Transporter 1 Is Required for Photoreceptor Synaptic Signaling But Not For Intrinsic Visual Functions
J. Neurosci., July 4, 2007; 27(27): 7245 - 7255.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.